AGOMAB THERAPEUTICS BVBA has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), China and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SURROZEN INC, AFFIMED THERAPEUTICS AG and LAVA THERAPEUTICS B V.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 3 | |
#2 | China | 2 | |
#3 | Australia | 1 | |
#4 | Brazil | 1 | |
#5 | Canada | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Mexico | 1 | |
#9 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Michieli Paolo | 10 |
#2 | Paolo Michieli | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019134927A1 | Hgf-met agonist for use in the treatment of cancer and colorectal fibrosis | |
WO2019134932A1 | Methods for promoting pancreatic islet cell growth | |
CN109689687A | Anti- MET antibody and its application |